Cholate Shunt, Oral Cholate Challenge and Endoscopic Lesions of Portal Hypertension: The SHUNT ‐V Study
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.18386 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Mitchell Shiffman und 10 weiteren Autor:innen. Beteiligte Einrichtung: Bon Secours Liver Institute of Virginia, Richmond, Virginia, USA. Hauptthemen laut MEDLINE: Hypertension, Portal, Esophageal and Gastric Varices, Liver Cirrhosis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HepQuant, LLC.
Abstract (Originalsprache)
Background
The accuracy of current criteria for ruling out large oesophageal varices (LEV) and other endoscopic lesions of portal hypertension (PH) may be compromised by obesity and MASLD/MASH.
Aims
In the US multicentre SHUNT‐V study, we evaluated the disease severity index (DSI) for detecting LEV and other lesions of PH at endoscopy.
Methods
Subjects were adults with compensated cirrhosis scheduled for endoscopy to screen for varices. DSI was calculated from clearances of labelled cholates after oral and intravenous administration. DSI ≤ 18.3 was evaluated as a cut‐off for ruling out LEV with acceptance criteria of negative likelihood ratio < 0.52 and sensitivity > 85%.
Results
SHUNT‐V enrolled 306 subjects; 275 had both DSI and endoscopy, and 238 had Child–Pugh A cirrhosis (52.1% MASLD/MASH, 25.2% chronic hepatitis C and 15.6% alcoholic liver disease; 87% were overweight, 64% were obese and 54% had diabetes). AUROCs for DSI ranged from 0.81 to 0.82 for LEV and 0.79 to 0.80 for all significant PH lesions. DSI 18.3 had sensitivity 96.3%–100% for LEV and 97.3%–100% for all significant PH lesions. If DSI ≤ 18.3 were used as the sole determinant to defer EGD, 27%–35% of EGDs could have been avoided with 0%–3.7% of LEV and 0%–2.7% of all significant PH lesions missed.
Conclusions
HepQuant DSI predicts the likelihood of LEV and significant PH lesions across a spectrum of patient characteristics and disease aetiologies. DSI, based on liver function and portal‐systemic shunting, can aid in the decision to defer endoscopy for varices in patients with Child–Pugh A cirrhosis. Trial Registration: The SHUNT‐V study was registered at ClinicalTrials.gov (NCT03583996)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Bon Secours Liver Institute of Virginia, Richmond, Virginia, USA.
- University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Mayo Clinic, Rochester, Minnesota, USA.
- Saint Louis University School of Medicine, St. Louis, Missouri, USA.
- Syneos Health, Morrisville, North Carolina, USA.
- HepQuant, LLC, Denver, Colorado, USA.
ORCID-Profile: Michael P McRae, Gregory T Everson
Förderung
- HepQuant, LLC
Zitieren
APA
Shiffman, M., Reddy, K. R., Leise, M. D., Qureshi, K., Smith, A. D., Helmke, S., Kittelson, J., McRae, M. P., Imperial, J. C., Everson, G. T., & SHUNT‐V Investigators (2025). Cholate Shunt, Oral Cholate Challenge and Endoscopic Lesions of Portal Hypertension: The SHUNT ‐V Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18386
Vancouver
Shiffman M, Reddy KR, Leise MD, Qureshi K, Smith AD, Helmke S, et al. Cholate Shunt, Oral Cholate Challenge and Endoscopic Lesions of Portal Hypertension: The SHUNT ‐V Study. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.18386
BibTeX
@article{Shiffman2025,
author = {Shiffman, Mitchell and Reddy, K Rajender and Leise, Michael D and Qureshi, Kamran and Smith, Alastair D and Helmke, Steve and Kittelson, John and McRae, Michael P and Imperial, Joanne C and Everson, Gregory T and SHUNT‐V Investigators, SHUNT‐V Investigators},
title = {Cholate Shunt, Oral Cholate Challenge and Endoscopic Lesions of Portal Hypertension: The SHUNT ‐V Study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.18386}
}
EUVIMED